Platelet-activating factor stimulates phosphatidylinositol turnover in human platelets as indicated by [32P]phosphatidate accumulation in platelets pre-labelled with [32p]p;, and by [3Hlphosphatidate accumulation and [3Hlphosphatidylinositol loss in platelets pre-labelled with [3Hlarachidonate. These effects of platelet-activating factor are direct and are independent of the production and/or release of endogenous platelet agonists such as ADP, 5-hydroxytryptamine and thromboxane A2.
2 -Acetyl -1 -alkyl -sn -glycero -3 -phosphocholine, also known as platelet-activating factor, was originally reported to be a basophil-derived mediator of inflammation and anaphylaxis (Benveniste et al., 1972) . It is now known to be produced by other cells, including human platelets activated by thrombin or ionophore A23187 (Chignard et al., 1979) . Platelet-activating factor induces aggregation of platelets of several species (Benveniste et al., 1972) , including man (MacIntyre & Westwick, 1981) . As it is produced by human platelets and is a potent inducer of human platelet activation, platelet-activating factor may function as an endogenous mediator of aggregation distinct from ADP and arachidonate metabolites (Vargaftig et al., 1981) .
The initial stage in the activation of platelets by agonists, such as ADP, collagen and thrombin, is combination of the agonist with a specific surfacemembrane receptor (Mills & Macfarlane, 1976) . Desensitization studies (Satouchi et al., 1981) indicate that there are receptors for platelet-activating factor on human platelets. In platelets, the major biochemical intermediaries that translate agonistreceptor combination into a cellular response are cyclic AMP and Ca2+. An elevated intracellular cyclic AMP concentration is associated with inhibition of platelet function (Haslam et al., 1978) , whereas platelet activation is associated with an increase in cytosolic free [Ca2+] (Rink et al., 1981) . Michell (1975) has suggested that an increase in cytosolic free [Ca2+1 is a consequence of agonistinduced turnover of membrane phosphatidylinositol. There is evidence that ADP and thrombin stimulate phosphatidylinositol turnover in platelets (Lloyd et al., 1972; Rittenhouse-Simmons, 1981) , and the mechanisms of the thrombin effect have been analysed in detail (Lapetina, 1982) . It is proposed that agonist-receptor combination activVol. 212 ates a phosphatidylinositol-specific phospholipase C, which hydrolyses phosphatidylinositol to diacylglycerol, which in turn is phosphorylated to phosphatidate. Phosphatidate may then be converted into phosphatidylinositol to complete the cycle, or acted upon by a phosphatidate-specific phospholipase A2 to yield lysophosphatidate (Billah et al., 1981) .
Phosphatidate and lysophosphatidate are calcium ionophores (Tyson et al., 1976; Gerrard et al., 1979) and may directly translocate calcium to the cytosol. In the present study we examined the effects of purified platelet-activating factor on phosphatidylinositol turnover in human platelets. Our results indicate that human platelet activation induced by platelet-activating factor is mediated, at least in part, by augmenting the turnover of phosphatidylinositol.
Experimental Preparation and labelling ofplatelets
Blood was obtained from the antecubital vein of healthy human volunteers, predominantly those who denied taking drugs known to affect platelet function. In some instances, we used donors who had ingested 600mg of aspirin 2 days previously. Blood was collected in 10% (v/v) trisodium citrate (0.13 M) and centrifuged (10OOg for 4min at 15-200C) . The supernatant platelet-rich plasma was aspirated, pelleted by centrifugation (800g for 10min at 15-200 C) in the presence of prostaglandin 12 (0.3,pM) (Moncada et al., 1982) and resuspended in a calcium-free phosphate-free buffer [150 mM-NaCl/ 4 mM-KCl/1 mM-MgCl2/10 mM-dextrose/5 mM-4-(2- at room temperature (Lloyd et al., 1972) .
Lipid extraction and t.l.c.
Platelet lipids were extracted essentially by method B of Lloyd et al. (1972) , dried at 400C under N2 and stored at -200C until use. The lipids were redissolved in 0.15 ml of chloroform/methanol (9:1, v/v) and spotted on silica-gel t.l.c. plates for two-dimensional separation of phospholipids (Yavin & Zutra, 1977) . In some cases 5,ug of carrier phosphatidate was used. Individual spots were visually detected by exposure to I2 vapour and/or autoradiography on Ilford 25 EP X-ray film (15-20h) . Spots corresponding to phosphatidylinositol and phosphatidate were scraped into vials and counted for radioactivity in a liquid-scintillation spectrometer.
Assays
Platelet aggregation was measured photometrically and release of platelet-dense granule constituents (ADP, 5-hydroxytryptamine) was monitored by using an isotope (5-hydroxy[t4C]tryptamine) pre-labelling technique (MacIntyre et al., 1978) . Protein was determined by the method of Lowry et al. (1951) .
Materials 2-Acetyl-1 -heptadecyl -sn-glycero-3 -phosphocholine, a gift from Dr. R. N. Saunders (Sandoz), was dissolved in iso-osmotic NaCl containing 0.25% bovine serum albumin. Prostaglandin 12, donated by Dr. J. E. Pike (Upjohn), was prepared as described previously (MacIntyre, 1979 [5,6,8,9,11,12,14,15- 3H]arachidonic acid (sp. radioactivity 127Ci/mmol) were from Amersham International.
Results and discussion
Platelet responsiveness (aggregation) induced by platelet-activating factor gradually declines with time after platelet preparation (McManus et al., 1981) . In the present study, agonist additions to platelets were routinely performed between 3 and 4 h after blood sampling. Platelets prepared under radiolabelling conditions aggregated when exposed to plateletactivating factor (11 nM-i.1 uM) (Fig. 1) . Platelet-activating-factor-induced human platelet aggregation Plasma-free suspensions of platelets (0.17 ml) prepared under radiolabelling conditions (see the Experimental section) were exposed to plateletactivating factor at the concentrations indicated, and aggregation was monitored photometrically. was by Student's t test. *P < 0.05; **P < 0.001.
of the glycerol backbone of phospholipids. Phosphatidate accumulation by platelets precedes deacylation of arachidonate from the phospholipids of stimulated platelets (Lapetina & Cuatrecasas, 1979 Platelet-activating-factor-induced human platelet activation is associated with the synthesis anid/or secretion of thromboxane A , ADP and 5-hydroxytryptamine (MacIntyre & Westwick, 1981) . The effects of platelet-activating factor on phosphatidylinositol turnover could be secondary to the action of these endogenous platelet agonists. We can tryptamine. Hence the effects of platelet-activating factor are direct and are independent of released ADP, 5-hydroxytryptamine and thromboxane A2.
Platelet activation is dependent on an increase in cytosolic free [Ca2+1 (Rink et al., 1981) , and stimulation of phosphatidylinositol turnover has been implicated in calcium gating (Michell, 1979) and in platelet responses to ADP, collagen and thrombin (Lloyd et al., 1972; Mauco et al., 1979; Rittenhouse-Simmons, 1981) . The mechanisms of platelet-activating-factor-induced platelet activation have been examined mainly using rabbit platelets. In that species, platelet-activating factor has been reported to stimulate an influx of 45Ca2+ (Lee et al., 1981) and to stimulate phosphatidylinositol metabolism (Shukla & Hanahan, 1982) . Using human platelets, we have shown that platelet activation induced by platelet-activating factor is selectively inhibited by the calcium-'antagonist' drugs verapamil and methoxyverapamil (MacIntyre & Shaw, 1982) . This could indicate that the effects of platelet-activating factor on human platelets are more dependent on increased calcium availability than are the effects of other agonists. We contend that activation of human platelets induced by platelet-activating factor could be modulated, at least in part, by stimulation of phosphatidylinositol turnover.
